Senior Benefit Assistance is a licensed Medicare agency. This guide was written by our licensed agents in October 2026 to explain the customs rule change and what it means for prescriptions ordered from Canada.
For more than twenty years, a quiet workaround has helped millions of Americans afford their prescriptions: ordering a 90-day supply by mail from a licensed pharmacy in Canada, where the same drugs cost far less. This fall, many of them braced for a U.S. customs deadline, October 22, 2026, that was expected to make that route much harder.
That deadline did not take effect. On October 22, 2026, U.S. Customs and Border Protection (CBP) postponed it to January 20, 2027. Here's what actually changed, what did not, and where the facts end and the fear begins.
What the rule does
The "de minimis" exemption was the rule that let packages valued under $800 clear customs with minimal processing. That duty-free treatment ended on August 29, 2025, under Executive Order 14324, "Suspending Duty-Free De Minimis Treatment for All Countries" (July 30, 2025). It did not end in October 2026. Under a CBP message issued July 9, 2025 (CSMS #65581311), all FDA-regulated products must be submitted to the Food and Drug Administration (FDA) for review, and the prior low-value exemptions were rescinded. The FDA decides whether to admit or refuse each prescription-drug shipment.
October 22, 2026 was the previously scheduled compliance date for international mail carrying agency requirements, such as FDA-regulated drugs, to move to formal entry or to a new electronic informal process called Entry Type 13. On October 22, 2026, CBP postponed that compliance date to January 20, 2027, in a notice titled "Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process; Delayed Compliance Extension" (91 FR 66638). A companion notice modified the Entry Type 13 test (91 FR 66707). In plain terms: the deadline moved, and no new formal-entry requirement took effect on October 22, 2026.
What the rule does not do
Here is where honesty matters, because community boards are split on this:
- There is no ban on personal importation from Canada. None of these actions bans ordering prescription drugs from Canadian pharmacies, and no new formal-entry requirement took effect on October 22, 2026.
- The rules already in effect still add friction. De minimis treatment ended in August 2025, and the FDA reviews every FDA-regulated product in the mail. That can mean delays, and the FDA decides whether to admit or refuse each shipment. Personal importation remains what it has long been in practice: technically restricted, with the FDA exercising enforcement discretion.
Both things are true: no ban took effect, and the mail route is under more scrutiny than it used to be. The next date that matters is January 20, 2027, and anyone telling you the route already closed in October 2026 is working from the old schedule.
Who this hits
Roughly 2.3 million Americans buy drugs from abroad, according to a 2020 medical-journal study. They're often people on fixed incomes taking daily medications for diabetes, heart conditions, or blood clots, people for whom the U.S. price is simply not payable.
Legitimate ways to lower the bill
Whatever happens with the mail rules, these paths do not depend on them:
- Ask about generics. The generic version of your drug may cost a fraction of the brand, sometimes a few dollars for a three-month supply at a retail pharmacy. Ask your doctor whether a generic is appropriate for your condition, and your pharmacist what it costs on your plan.
- Check your 2027 formulary during AEP. Plans change drug tiers every year. A drug that was affordable in 2026 may sit on a different tier in 2027, or a different plan may cover it better. Run your exact prescriptions through Medicare's Plan Finder and compare total yearly cost, not just the premium.
- Know the 2027 Part D cap. The most you'll pay out of pocket for covered Part D drugs in 2027 is $2,400. If your costs are high, that cap is your ceiling for covered drugs.
- Talk to your pharmacist. Pharmacists see the real prices across plans and programs every day. A five-minute conversation can surface options, such as generics, therapeutic alternatives your doctor might approve, or assistance programs, that no website will.
- Write to your representatives. As one board member put it: "Write to your representatives." Drug affordability is a policy problem, and policymakers count the letters.
The bottom line
The customs changes are real, but the October 2026 deadline was postponed, not imposed: the new date to watch is January 20, 2027. What has already changed, the end of de minimis treatment in August 2025 and FDA review of every FDA-regulated product, makes the mail route less simple than it was. None of it changes the fundamentals: know your formulary, compare plans during the Annual Enrollment Period (October 15 – December 7), ask about generics, and talk to your pharmacist.
Sources: Executive Order 14324 (July 30, 2025); CBP CSMS #65581311 (July 9, 2025); 91 FR 66638 and 91 FR 66707 (October 22, 2026); CMS CY2027 Announcement (April 6, 2026); JAMA Network study (2020). Beneficiary experiences paraphrased from public community-board discussions, October 2026.